Price
$803.48+20.29%Social Signal Score
Analyst Ratings
49 analysts52-week range
- Last close
- $803.48
- Off 52w high
- -1.1%
- 200-day average
- $720.14
- vs 200-day
- +11.6%
Revenue
$4.29B+251.66%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Leonard S. Schleifer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15,410
- Beta
- 0.24
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 6.95
Financials
Revenue
$4.29B+251.7%Net Income
$1.30B+389.8%EBITDA
$1.66B+322.0%Free Cash Flow
$334.30M-37.2%EPS (diluted)
$12.20+437.4%Shares Outstanding (diluted)
106.80M-8.4%Operating Expenses
$2.29BCash & Debt
$7.99BReturn of Capital
$1.27BRevenue by Segment (annual)
$14.34BDividend per Share
$0.94Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.34B | $4.50B | $43.07 |
| 2024 | $14.20B | $4.41B | $40.90 |
| 2023 | $13.12B | $3.95B | $37.05 |
| 2022 | $12.17B | $4.34B | $40.51 |
| 2021 | $16.07B | $8.08B | $76.40 |
| 2020 | $8.50B | $3.51B | $32.65 |
| 2019 | $6.56B | $2.12B | $19.38 |
| 2018 | $6.71B | $2.44B | $21.29 |
| 2017 | $5.87B | $1.20B | $11.27 |
| 2016 | $4.86B | $895.52M | $8.55 |
| 2015 | $4.10B | $636.06M | $6.17 |
| 2014 | $2.82B | $348.07M | $3.36 |
| 2013 | $2.10B | $424.36M | $4.23 |
| 2012 | $1.38B | $750.27M | $7.92 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from REGN's reported EPS growth of 13.9% a year over 13 years.
- EPS in 5 years
- $82.56
- Implied price
- $1,486
- Return from $735.20
- 15.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $738.85 — today's price is already 0.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| 3.9% | -3.2% | 1.2% | 5.0% | 8.3% | 11.2% |
| 8.9% | 1.5% | 6.1% | 10.1% | 13.5% | 16.6% |
| 13.9% | 6.1% | 11.0% | 15.1% | 18.7% | 21.9% |
| 18.9% | 10.8% | 15.9% | 20.2% | 23.9% | 27.3% |
| 23.9% | 15.5% | 20.7% | 25.2% | 29.1% | 32.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
20-66.67%Social Signal Score
Mentions (35)
- News (RSS)seekingalpha·1d ago·Negative
Regeneron: The Easy Money Has Been Made (Rating Downgrade)
View source ↗ - News (Marketaux)insidermonkey.com·3d ago·Positive
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets That makes Vertex Pharmaceuticals Incorp[+223 characters]
View source ↗ - Newsbenzinga.com·3d ago·Negative
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Thursday shared clinical trial results for two investigational therapies targeting recurrent ovarian cancer and muscle loss prevention during weight management.
View source ↗ - News (RSS)zerohedge·3d ago·Neutral
Futures Rise, Yields and Oil Drop Ahead Of Key Jobs Report Futures Rise, Yields and Oil Drop Ahead Of Key Jobs Report US futures climbed and bond yields reversed an earlier rise, as a drop in oil prices provides a tailwind in calm trading following a week in which markets were lashed by sharp swings in yields, with the US payrolls report still to come. As of 8:15am ET, S&P 500 futures were up 0.4% after Thursday’s close left the index headed for its worst week since August; Nasdaq 100 contracts
View source ↗ - News (RSS)seekingalpha·4d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
View source ↗ - News (Marketaux)gurufocus.com·4d ago·Neutral
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Trial Results for Ovarian Cancer On October 01, 2026, Regeneron [+225 characters]
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
View source ↗ - News (RSS)investing·4d ago·Negative
Regeneron reports 73% response rate for ovarian cancer drug trial
View source ↗ - News (RSS)seekingalpha·4d ago·Negative
Sanofi to pay Regeneron up to $8B to expand long-acting drug pipeline
View source ↗ - News (RSS)wsj·5d ago·Negative
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
View source ↗ - News (RSS)investing·5d ago·Neutral
Regeneron, Sanofi expand alliance with $1 billion upfront deal
View source ↗ - Newsreuters.com·5d ago·Negative
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.
View source ↗ - Newszacks.com·6d ago·Neutral
REGN or ILMN: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newsbenzinga.com·7d ago·Negative
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) stock is trading lower on Monday, probably in reaction to positive data from Kodiak Sciences Inc.'s (NASDAQ:KOD) data from the Phase 3 DAYBREAK trial for wet age-related macular degeneration (wAMD).
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts Regeneron Pharmaceuticals NASDAQ: REGN executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch.
View source ↗ - Newsfool.com·13d ago·Positive
Is Regeneron Stock a Bargain Below $800? Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff.
View source ↗ - News (RSS)fool·20d ago·Neutral
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·21d ago·Neutral
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth Regeneron Pharmaceuticals NASDAQ: REGN executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance.
View source ↗ - News (Marketaux)seekingalpha.com·26d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·27d ago·Positive
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
View source ↗ - News (RSS)fool·31d ago·Positive
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? They could both outperform the market over the medium term, but one appears to have a clear edge.
View source ↗ - News (RSS)yahoo·39d ago·Negative
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
View source ↗ - News (RSS)yahoo·40d ago·Neutral
Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
View source ↗ - News (RSS)investing·41d ago·Neutral
Regeneron selects Veeva Vault CRM for global deployment
View source ↗ - Newsseekingalpha.com·42d ago·Positive
Regeneron: Why I Still See Upside After The Rally Regeneron Pharmaceuticals ends August on a high note. The decline in U.S. sales of Eylea following the launch of biosimilars is no longer putting pressure on REGN stock. That's because REGN's Dupixent sales reached €5.15 billion in the second quarter, up 23.6% sequentially.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
View source ↗ - Newsreuters.com·47d ago·Negative
US FDA approves Regeneron's rare bone disorder drug The U.S. FDA on Wednesday approved Regeneron's experimental drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
View source ↗ - Newszacks.com·55d ago·Positive
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock? Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
View source ↗
Earnings
Fri, Oct 30(in 3 weeks)
Consensus estimate $15.99 per share
Typical surprise +7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$14.29 vs $10.16beat
- Wed, Apr 29$9.47 vs $8.91beat
- Fri, Jan 30$11.44 vs $10.74beat
- Tue, Oct 28$11.83 vs $9.65beat
- Fri, Aug 1$12.89 vs $8.43beat
- Tue, Apr 29$8.22 vs $8.62miss
Estimates and results for REGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by REGN officers and directors.
- Bought
- —
- Sold
- $7.8m
0 trades
76 trades
- Mccourt Marionsold
- Mccourt Marionsold
- Guarini Kathrynsold
- Guarini Kathrynsold
- Zoghbi Huda Ysold
- Ryan Arthur Fsold
- Ryan Arthur Fsold
- Ryan Arthur Fsold
24 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Mar 13, 2026 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed May 26, 2025 (46d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed May 26, 2025 (46d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed May 15, 2025 (44d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Sell$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Mar 13, 2025 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Feb 12, 2025 (28d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 11, 2025 (18d later)Sell$1,001 - $15,000
- Jonathan Jacksonhouse · IL01 · disclosed Dec 12, 2024 (29d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.